Humira: The First $20 Billion Drug
The American Journal of Managed Care · 01.02.2023 · 29 (2) · 78-80
DOI: 10.37765/ajmc.2023.89315 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The American Journal of Managed Care, online erschienen am 08.02.2023. Verfasst von Jason B Gibbons und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD 21205. Email: jgibbo13@jhu…. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 25-mal zitiert (Crossref). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD 21205. Email: jgibbo13@jhu.edu.
Förderung
- NCI NIH HHS
Zitieren
APA
Gibbons, J. B., Laber, M., & Bennett, C. L. (2023). Humira: The First $20 Billion Drug. The American Journal of Managed Care, 29(2), 78-80. https://doi.org/10.37765/ajmc.2023.89315
Vancouver
Gibbons JB, Laber M, Bennett CL. Humira: The First $20 Billion Drug. The American Journal of Managed Care. 2023;29(2):78-80. doi:10.37765/ajmc.2023.89315
BibTeX
@article{Gibbons2023,
author = {Gibbons, Jason B and Laber, Micaela and Bennett, Charles L},
title = {Humira: The First $20 Billion Drug},
journal = {The American Journal of Managed Care},
year = {2023},
volume = {29},
number = {2},
pages = {78--80},
doi = {10.37765/ajmc.2023.89315}
}
EUVIMED